Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit has been formally approved by the Indian Council of Medical Research (“ICMR”).
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
Genedrive enters distribution agreement with Mountain Horse Solutions
New clinical guidance in the UK supports assay
Further to the announcements on 29 January 2021, Braveheart Investment Group plc (AIM: BRH), is pleased to provide an update concerning progress to develop a COVID-19 test that Paraytec Limited
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces the first shipments to the United States of its Genedrive® 96 SARS-CoV-2 Kits.
Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, confirms that its Genedrive 96 SARS CoV-2 Kit continues to detect all known variants of COVID-19, including the newest variants released
Genedrive notifies FDA of its intent to distribute to SARS-CoV-2 PCR test in the USA
